STAT+: Pharmalittle: Pfizer to pay $11.6 billion for Biohaven; pharmacy chains face a novel trial to determine opioid liability
Good morning, everyone, and how are you today? We are doing just fine, thank you, after a few days of distractions, schlepping, and hand holding. But as threatened, we have returned and are now quaffing cups of stimulation as we ease back into our routine. Our choice of stimulation today is Jack Daniels and, yes, it is ground by the same famous distillery. Feel free to join us. Meanwhile, we have assembled a few items of interest for you to peruse. On that note, we wish you a productive and meaningful day. And of course, do stay in touch. We relish postcards and telegrams detailing government and corporate secrets. …
Pfizer has agreed to buy U.S. biotech company Biohaven Pharmaceuticals for $11.6 billion in cash, its biggest deal in more than five years, The Financial Times writes. With record revenues linked to the success of its Covid-19 vaccine and antiviral pill forecast to fade, Pfizer has been hunting for acquisitions to sustain its growth. Biohaven specializes in drugs that target neurological diseases and rare disorders. Its best-known drug is Nurtec ODT, which has been approved for both acute treatment and prevention of migraine in adults. Pfizer invested $350 million in the company in November, acquiring 2.6% of its shares. More from STAT.
Continue to STAT+ to read the full story…
